Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination...

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Protein kinase inhibitors are effective cancer treatments, but targetable kinases are scarce in T cell acute lymphoblastic leukemia (T-ALL).
• Kinase activation can occur without genetic defects, necessitating alternative methods to identify therapeutic vulnerabilities.
• Phosphoproteomics offers insights into pathway activation and signaling networks crucial for targeted therapy development.

Purpose of the Study:

• To identify targetable kinases in T-ALL using global phosphoproteomic profiling.
• To establish a comprehensive phosphoproteomic dataset for T-ALL cell lines.
• To validate potential therapeutic targets and combination treatments for T-ALL.

Main Methods:

• Mass spectrometry-based global phosphoproteomic profiling of 11 T-ALL cell lines.
• Comprehensive dataset generation including phosphosites, phosphoproteins, and kinases.
• Ex vivo validation of identified targets and drug combinations using patient-derived xenografts.

Main Results:

• A dataset of 21,000 phosphosites on 4,896 phosphoproteins, including 217 kinases, was generated.
• Active Src-family kinases and cyclin-dependent kinases signaling pathways were identified.
• Inhibition of the Insulin Receptor/Insulin-like Growth Factor 1 Receptor (INSR/IGF-1R) axis enhanced sensitivity to dasatinib treatment.

Conclusions:

• Phosphoproteomics is a valuable tool for identifying targetable kinases in T-ALL.
• Targeting specific signaling pathways, like INSR/IGF-1R, can overcome resistance to existing therapies.
• This study provides a proof-of-concept for phosphoproteomics-guided personalized T-ALL treatment strategies.